Assess recurrence risk after treatment
NOW FDA Approved 
NEW Innovative Features 
NEW Innovative Features 
Transform the way you see what’s next, now.
Discover our portfolio of revolutionary liquid and tissue tests that span the cancer care continuum, all with the convenience of a single testing partner.
Testing solutions for all stages of cancer.
See how Guardant Complete® can help answer critical questions throughout the patient care journey.
Guide treatment selection for newly diagnosed patients
Monitor treatment response
Identify next treatment options at progression
More oncologists choose Guardant®.
Here’s why.
Strong clinical utility that meaningfully improves patient outcomes.2
Rigorous analytical validation to prove reliable test performance and sensitivity.3
Comprehensive clinical validation to ensure test performance meets the highest standards.3
Fast turnaround times to make genomic insights available when treatment decisions are being made.3
Broad access through extensive payer coverage, financial assistance programs, and regulatory alignment.3
Explore some of the 1500+ publications and abstracts backing our tests.
Exceptional cancer care is more than just testing.
Get to know the power
behind Guardant tests.
Only InfinityAI unlocks novel actionable biomarkers from genomic, epigenomic, and transcriptomic insights to power advanced testing features.
Experience comprehensive support throughout the care continuum.
Get comprehensive support at every step, including on-demand medical experts, financial assistance, and mobile phlebotomy services.
MRD, minimal residual disease.
*Based on chart audit data of test utilization, April 2026.
Important note: Guardant360 Tissue was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA. Guardant Hereditary Cancer was developed as an LDT and is not cleared or approved by the US FDA.
InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.
References: 1. Guardant Health data on file. Q1 2026 late-stage cancer chart audit. April 2026. 2. Aggarwal C, Marmarelis ME, Hwang WT, et al. Association between availability of molecular genotyping results and overall survival in patients with advanced nonsquamous non–small-cell lung cancer. JCO Precis Oncol. 2023;e2300191. doi:10.1200/PO.23.00191 3. Guardant Health data on file. April 2026. Guardant Health, Inc. Redwood City, CA.